89Zr-DFO-girentuximab imaging shows promise in identifying, stratifying renal tumors : vimarsana.com

Findings from the phase 3 ZIRCON trial showed that imaging with 89Zr-DFO-girentuximab could improve the identification and risk stratification of patients with renal tumors.

Related Keywords

United States , American , Brian Shuch , Alvin Carrie Meinhardt , American Urological Association Annual Meeting , Kidney Cancer Research , Kidney Cancer Program , Urological Association Annual , Carrie Meinhardt Endowed Chair , News , Conference , Nct03849118 , Hase 3 Zircon Trial , 89zr Dfo Girentuximab ,